DWC202216

DWC202216 is an investigational drug evaluated in a Phase 1 clinical trial for its safety and pharmacokinetic profile in healthy adult volunteers. The study is designed as a randomized, open-label, oral, single-dose, two-way crossover trial comparing DWC202216 with DWJ1543. The primary endpoints are the maximum plasma concentration (Cmax) and area under the curve to last measurable concentration (AUClast) of DWJ1543. The developer and lead sponsor of this study is Daewoong Pharmaceutical. No information on mechanism of action, active ingredient, or therapeutic indication beyond its use in bioequivalence studies has been disclosed[1][3].